Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a common, progressive lung disorder characterised by persistent airflow limitation that is not fully reversible, arising from chronic inflammation of the airways and destruction of the lung parenchyma. It is most often caused by long-term exposure to noxious particles and gases, predominantly tobacco smoke.

Definition

COPD is a chronic respiratory condition defined by persistent, typically progressive airflow limitation that is not fully reversible, caused by airway and alveolar abnormalities (chronic bronchitis and emphysema) usually due to significant exposure to noxious particles or gases.

Scope

This entry describes COPD as a pathological process: the airway and parenchymal lesions of chronic bronchitis and emphysema, the resulting airflow obstruction, and the disease's epidemiology. It is reference-educational and does not provide bronchodilator, inhaled-steroid, dosing, or individualised management advice.

Core questions

• What balance of small-airway disease and emphysematous parenchymal destruction produces the airflow limitation?
• How does chronic inflammation lead to mucus hypersecretion, airway remodelling, and loss of elastic recoil?
• Why is the airflow obstruction described as persistent and not fully reversible?
• How do exposures, chiefly tobacco smoke, drive disease onset and progression?

Key concepts

• Persistent, not fully reversible airflow limitation
• Chronic bronchitis (airway) versus emphysema (parenchymal) components
• Loss of elastic recoil and air trapping
• Small-airway inflammation and remodelling
• Protease-antiprotease and oxidant-antioxidant imbalance
• Exacerbations
• Tobacco smoke and inhaled-particle exposure

Mechanisms

Chronic inhalation of noxious particles, most commonly cigarette smoke, provokes inflammation throughout the airways and alveoli. In the airways this produces mucus-gland hyperplasia, mucus hypersecretion, and remodelling that narrows the small airways (the chronic bronchitis component). In the parenchyma, an imbalance between proteases and antiproteases and between oxidants and antioxidants leads to destruction of alveolar walls and loss of elastic recoil (emphysema). The combined result is expiratory airflow limitation and air trapping, measured physiologically as a reduced ratio of forced expiratory volume in one second to forced vital capacity, as summarised by Christenson and colleagues and by the GOLD reports.

Clinical relevance

COPD is defined and graded by spirometric airflow limitation together with symptoms and exacerbation history, and the GOLD reports provide the widely used framework for assessment. Understanding the underlying airway and parenchymal pathology clarifies why the obstruction persists. This entry is descriptive reference material and is not a basis for individual treatment decisions.

Epidemiology

COPD is among the leading causes of death worldwide in Global Burden of Disease analyses and a major source of chronic disability. Tobacco smoking is the dominant risk factor in many populations, while biomass-fuel smoke and occupational and air-pollution exposures contribute substantially, particularly in lower-income settings.

History

The clinical syndromes of chronic bronchitis and emphysema were long described separately before being unified under the concept of obstructive lung disease as spirometry became standard. The discovery that alpha-1 antitrypsin deficiency causes early emphysema supported the protease-antiprotease hypothesis, and successive GOLD reports standardised contemporary definition and staging.

Debates

How should COPD be classified and staged?

Frameworks have shifted from spirometry-only severity grading toward multidimensional assessment incorporating symptoms, exacerbation risk, and phenotypes, and the optimal classification remains an area of revision across successive GOLD updates.

Seminal works

• christenson-2022
• agusti-2023-gold

Frequently asked questions

What is the difference between chronic bronchitis and emphysema in COPD?

Chronic bronchitis refers to the airway component with mucus hypersecretion and small-airway narrowing, while emphysema refers to destruction of alveolar walls and loss of elastic recoil; most patients have a mixture of both contributing to airflow obstruction.

Why is the airflow obstruction in COPD called not fully reversible?

Because it arises from structural airway remodelling and parenchymal destruction rather than purely from reversible airway muscle constriction, the obstruction persists and does not return fully to normal after bronchodilation.